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Abstract
Methods of investigation: Biochemical investigations (to determine the ALAT, ASAT, bilirubin, thymol test, prothrombinic index, GGTP), clinical 
investigations (haemoleucogram), serological investigations (to determine the anti-HVC IgM), molecular biological investigations (to determine the 
ARN-VHC quantitative test by PCR Real-Time), immunological investigations (to determine the immune status spectrum). Citomix treatment in patients 
with HVC contributed to the improvement of clinical symptoms; the improvement of cytolysis syndrome indices indicating the hepatoprotective features 
of the drug; a moderate decreasing of anti-HVC IgM titres with a bias in 2; an improvement of the immune status in 66.6% of the patients enrolled in the 
study, which confirm the immunomodulatory proprieties of the drug.
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Лечение Цитомиксом больных хроническим вирусным гепатитом С
Лечение Цитомиксом проводилось у 30 больных хроническим вирусным гепатитом С в течение 4-х месяцев.  Методы исследования: 
биохимические (определение билирубина, АЛАТ, АСАТ, тимоловой пробы, протромбинового индекса, ГГТП), гемолейкограммы, серологические 
(определение anti-HVC IgM), моллекулярно-биологические (определение ARN-VHC количественный тест методом PCR Real Time), 
иммунологические (определение спектра иммунологического статуса).  Лечение Цитомиксом пациентов ХВГС способствовало улучшению, 
вплоть до исчезновения клинических симптомов, показателей цитолитического синдрома, что говорит в пользу гепатопротективного действия, 
умеренного уменьшения титров Anti-VHC IgM, с исчезновением симптомов у 2 пациентов, улучшения имунного статуса с нормализацией 
показателей у 66,6% исследуемых пациентов.  Это доказывает иммуномодуляторные свойства препарата.
Ключевые слова: цитомикс, хронический вирусный гепатит С.
Introduction
Viral hepatitis continues to be a worldwide public health 
problem.  According to their incidence they follow the acute 
respiratory and acute intestinal infections.  But the significance 
of tackhling of this problem is imposed not only by the high 
morbidity, but also because of its severity and the consequen-
ces with a high biological and social impact.
The virus hepatitis C infection is a major public health 
problem.  About 3% of the world´s population is infected with 
hepatic virus C, and the percentage of chronicity is rather high 
(50-90%).  The progression rate in patients with viral chronic 
hepatitis C to hepatic cirrhosis is 5-10% in a 10 years interval and 
20% after 20 years of evolution, being less in young patients and 
women.  The risk of hepatocellular cancer in patients with cir-
rhosis with VHC is 1-2.6-6.9% according to bibliographical data.
New conceptions of treatment appeared in medical practice, 
including antiviral treatment.  But clinical practice shows that 
antiviral treatment cannot be administered in all cases taking into 
consideration the high costs of these medicines and incomplete 
therapeutic effects in some cases (in case of viral chronic hepa-
titis C up to 50%).  So to study the new drugs it is necessary as 
it would would have benefic effects on the function of the liver.
The tasks of the study
1. To study the evolution of clinical symptomatology in 
patients with viral  chronic hepatitis C.
2. To essesse biochemical indices in dynamics (bilirubin, 
ALAT, ASAT, the thymol test, prothrombinic index, GGTP) 
in patients with viral chronic hepatitis C at the beginning of 
treatment, in two months and at the end of treatment.
3. To  essesse the changes of the immunological indices 
of patients with viral chronic hepatitis C at the beginning, in 
two months and at the end of treatment.
4. To essesse the changes of anti-HVC IgM titre at the 
beginning, in 4 months and at the end of treatment.
5. To assess the dynamics of viral load (through PCR Real 
Time, a quantitative test) at the beginning and at the end of 
treatment.
6. To determine the tolerance and side effects of the home-
opathic drug Citomix in patients with viral chronic hepatitis C.
Material and methods
Clinical investigations performed in 30 patients with chro-
nic viral hepatitis C, aged 21 to 71, the average age was 50.0 ± 
9.1 of which 15 were males and 15 women, 20 (66.7%) from 
urban area, and 10 (33.3%)  from rural areas. The length of 
the disease was from 1-5 years in 15 patients and from 7-15 
years in 15 patients.  The patients were administered treatment 
with Citomix.  The scheme prescription of the medicine was: 
3 granules twice a day sublingually in the morning and in the 
evening 15 minutes before the meals or an hour after meals 
for 4 months.
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Our clinical study included the use of homeopathic drug 
Citomix.
Characteristics of the drug
Citomix is a combined drug for profilaxis and treatment of 
bacterial and infectious diseases.  It is a homeopathic remedy 
in granules to be administered sublingually.
Composition
Ananassa 3x, Granulocyte colony stimulating factor 4c, 
9c, 15c, 30c; Hydrocotyle asiatica 3x; Interferon gamma 4c, 
Interleukin I beta 5c; Interleukin II 5c; Interleukin IV 4c; In-
terleukin VI 7c, 9c, 15c; Lymphatic vessel porcine 4c; Medulla 
ossis suis 4c; Mountain cranberry 3x; Thymus gland porcine 
4c; Saccharose.
The aim. To assess the efficiency of the homeopathic 
drug Citomix by estimating clinical-biological parametres in 
patients with viral chronic hepatitis C.
Methods of investigation.  Biochemical investigations (to 
determine the ALAT, ASAT, bilirubin, thymol test, prothrom-
binic index, GGTP), clinical investigations (haemoleuco-
gram), serological investigations (to determine the anti-HVC 
IgM), molecular biological investigations (to determine the 
ARN-VHC quantitative test by PCR Real-Time), immunologi-
cal investigations (to determine the immune status spectrum).
The results
After examining the obtained results in all the patients 
administered Citomix, a favourable evolution of the clinical 
symptomatology was established (tab. 1).
The analysis of tab. 1 shows that, treatment with Citomix 
contributed to a clinical improvement of symptomatology.
The assessment of biochemical parameters in patients in 
the study also shows an improvement as a result of Citomix 
administration for a 4 months period.
When analysing biological parameters we see that the 
average of transaminases both ALAT and ASAT had favo-
urable variations under the influence of Citomix treatment, 
the average values being at the beginning of treatment 1.36 ± 
0.9 and by the end 0.9 ± 1.0 (p < 0.05), while the ASAT being 
respectively 85.8 ± 47.8 and 74 ± 45.4 (p < 0.05), of thymol test 
5.0 ± 4.2 and 4.5 ± 3.2 (p < 0.05), GGTP 62.8 ± 107.8 and 43.9 
± 71.2, general bilirubin 18.9 ± 8.7 and 17.9 ± 8.1 (p < 0.05).
General bilirubin with high values determined in some 
patients was due to the indirect bilirubin (unconjugated), these 
patients having been diagnosed with Gilbert´s Syndrome.
According to data from tab. 2, the number of thrombocytes 
at the beginning of treatment was normal, 2 patients of 30 had 
a decreased number of thrombocytes at the beginning and at 
the end of  the treatment.  The anti-VHC IgM titre values and 
those of viral loads are to be found in tab. 3.
When analysing the indices included in tab. 3 we see that 
a moderate decreasing of the anti- VHC IgM titre from 81.8 ± 
71.1 till 70.6 ± 75.2 and no positive dynamics can be noticed. 
The dynamics of the immune status values of the patients 
included in the study is reflected in tab. 4.
From the data given in tab. 4 dealing with immune status 
we can conclude that there is an immunenosupression of the 
Table 1
Clinical symptomatology and dynamics in evolution in 
patients of the study group
No Symptoms
At the be-
ginning of 
treatment
In two 
months 
At the end 
of treat-
ment
1 Pains in the right costal side 3 (10.0%) - -
2 Asthenia 4 (13.3%) - -
3 Abdominal discomfort 2 (6.6%) - -
4 Inappetence 2 (6.6%) - -
5 Fatigue 4 (13,3%) - -
6 Malaise 2 (6.6%) - -
7 Bitterness in the mouth 1 (3.3%) - -
8 Perspirations 1 (3.3%) - -
9 Vertigos 3 (10.0%) - -
10 1 - 4 cm of the liver 21 (70.0%) 12 (40.0%) 8 (26.6%)
11 The spleen 5 (16.6%) 3 (10.0%) 2 (6.6%)
Table 2
The average values of biochemical and thrombocytes 
indices of the patients in the study
Nr.
d/o The index
Normal 
values
At the be-
ginning of 
treatment
In two 
months   
At the end 
of treat-
ment
1 ALAT 0.1-0.68 mmol/h/l 1.36 ± 0.9 1.5 ± 1.2 0.9 ± 1.0
2 ASAT 0-42 UI 85.8 ± 47.8 90 ± 50.5 74 ± 45.4
3 General bili-rubin 
13.0-19.0 
mcmol/l 18.9 ± 8.7   20.0 ± 9.6 17.9 ± 8.1
4 Thymol test 0-4 Un 5.0 ± 4.2 5.2 ± 3.7 4.5 ± 3.2
5 GGTP 5-45 U/l 62.8 ± 107.8 56.8 ± 96.0 43.9 ± 71.2
6 Thrombocytes 120.0-320.0
268.8 ± 
123.8
255.5 ± 
110.5
248.0 ± 
118.4
Table 3
Dynamics of average values of anti-VHC IgM  
titres and viral load of patients in study
Indices Normal values
At the beginning of 
treatment
At the end of 
treatment
Anti-VHC IgM - 81.8 ± 71.1 70.6 ± 75.2
ARN-VHC Negative 5035993.6 ± 7559378.6
9546417.6 ± 
1917777.9
Table 4
The immune status of patients included in the study
Indices Normal values
At the be-
ginning of  
treatment
In two 
months  
At the end 
of treatment
Leucocytes 4.5-8.0 5.4 ± 1.7 5.9 ± 1.4 6.0 ± 2.2
Limphocytes 1.2-2.4 1.9 ± 0.5 2.1 ± 0.7 2.2 ± 0.9
Ea-RFC 0.3-0.7 0.3 ± 0.1 0.4 ± 0.5 0.5 ± 0.4
Ea-RFCtot 0.9-1.5 0.8 ± 0.4 1.0 ± 0.5 0.9 ± 0.5
Ea-RFCterm    0-0.09 0.0 ± 0.1 0.0 ± 0.1 0.0 ± 0.1
TFR-E-RFC 0.7-1.1 0.5 ± 0.3 0.6 ± 0.4 0.7 ± 0.4
Limphocytes TFS 0.23-0.43 0.3 ± 0.2 0.4 ± 0.2 0.3 ± 0.2
EAC-RFC 0.18-0.32 0.4 ± 0.2 0.4 ± 0.2 0.4 ± 0.2
CIC ≤ 60 77/2 ± 65.1 48.7 ± 36.7 78 ± 46.0
LTL 4.0-7.0 8.4 ± 6.0 6.5 ± 3.0 7.4 ± 3.6
T/B 2.0-5.0 1.9 ± 0.9 3.4 ± 2.1 3.3 ± 1.5
TFR/TFS 2.0-4.0 2.2 ± 1.9 2.7 ± 6.2 2.5 ± 0.8
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III stage in 16.5% and of the II stage in 73.3% and a lympho-
cytosis B.  CIC had high values at the beginning of treatment 
(77.2 ± 65.1) and became normal (48.7 ± 36.7) (p < 0.05) in 2 
months from the administration of treatment, but it increased 
(78 ± 46.0) at the end of treatment.
Conclusions
Citomix treatment in patients with HVC contributed to the:
- improvement of clinical symptoms;
- the size of the liver became normal in 43.4% and in 10.0% 
of the spleen;
- the improvement of cytolysis syndrome indices, which 
indicates in favour of hepatoprotective features of the drug;
- a moderate decreasing of anti-HVC IgM titres with a bias 
in 2 was found;
- an improvement of the immune status was seen in 66.6% 
of patients enroled in the study, which confirm the immuno-
modulatory proprieties of the drug;
- citomix was well tolerated and no side effects were de-
termined.
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Контроль холестерина на поликлиническом уровне  
в профилактике артериальной гипертонии  
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Cholesterol Control in the Policlinics in the Prophylaxis of Arterial Hypertension and Cardiovascular Morbidity
 Cholesterol levels provide one of the few tools in assessing the degree of Arterial Hypertension and Cardiovascular Diseases, and control of cholesterol 
is an important preventative measure that can be taken at the policlinic level though necessary measurements are not performed on a regular basis for 
each patient. Results of the study show that a high cholesterol level is not only a risk factor for the development of AH and CVD, but also decreases the 
effectiveness of medical treatment of these diseases.  Strict adherence to recommended low-cholesterol diet normalizes the cholesterol level within a fixed 
time period of two years and increases the likelihood of successful treatment.  
Key words: arterial hypertension, cholesterol, cardiovascular diseases, risk factors.
Реферат
Результаты проведенного исследования показывают, что повышенное содержание общего холестерина в крови является не только фактором 
риска развития артериальной гипертонии и сердечно-сосудистой заболеваемости, но и снижает эффективность медикаментозной терапии 
этих заболеваний.  Максимальная выполняемость рекомендованной упрощенной холестериноснижающей диеты позволяет в определенный 
период времени (2 года) нормализовать содержание общего холестерина в крови.  Изыскание подходов по повышению приверженности 
пациентов к холестериноснижающей диете повышает эффективность медикаментозной терапии.
Ключевые слова: артериальная гипертензия, холестерин, сердечно-сосудистые заболевания, факторы риска.
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